An overview of growth hormone therapy in pediatric cases documented in the Kabi International Growth Study (Pfizer International Growth Database)

• Main Authors: Mitchell E. Geffner (Author), Michael B. Ranke (Author), Michael P. Wajnrajch (Author), for the Pfizer International Growth Database Strategic Executive Committee, Strategic Advisory Board, and International Board (Author)
• Format: Book
• Published: Korean Society of Pediatric Endocrinology, 2024-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 2287-1012; 2287-1292; 10.6065/apem.2346206.103
• Keywords: kabi international growth study; pharmaco-epidemiological study; recombinant human growth hormone; Pediatrics; RJ1-570
• Source: Annals of Pediatric Endocrinology & Metabolism, Vol 29, Iss 1, Pp 3-11 (2024)

The Kabi International Growth Study (KIGS) was first established in 1987 and is the largest pharmaco-epidemiological study of recombinant human growth hormone (rhGH). KIGS is aimed at evaluating long-term safety and treatment outcomes in pediatric subjects who received Genotropin rhGH therapy (Pfizer, New York, NY, USA) as prescribed by physicians in real-world clinical practice settings. KIGS data have been used to answer multiple research questions related to growth, growth prediction, and growth hormone treatment, leading to the publication of 129 peer-reviewed manuscripts and 24 biannual reports, outcomes from 10 expert meetings, and 3 books. The KIGS has shown that rhGH is safe and increases both the short-term height gain and adult height in patients with GH deficiency (GHD) and multiple other non-GHD conditions associated with short stature.